This time last year, Bradley Merrill Thompson was heartbroken over the Food and Drug Administration’s decision not to prioritize guidance on artificial intelligence/machine learning (AI/ML)-enabled device software functions.
In its annual A and B lists of guidance documents it plans to focus on in the coming fiscal year,...